These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20667950)

  • 1. Shifting views on lipid lowering therapy.
    Krumholz HM; Hayward RA
    BMJ; 2010 Jul; 341():c3531. PubMed ID: 20667950
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG).
    Javed U; Deedwania PC; Bhatt DL; Cannon CP; Dai D; Hernandez AF; Peterson ED; Fonarow GC
    Am Heart J; 2010 Dec; 160(6):1130-6, 1136.e1-3. PubMed ID: 21146668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attainment of low-density lipoprotein cholesterol goals in coronary artery disease.
    Kauffman AB; Olson KL; Youngblood ML; Zadvorny EB; Delate T; Merenich JA;
    J Clin Lipidol; 2010; 4(3):173-80. PubMed ID: 21122649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].
    Olsson AG
    Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387
    [No Abstract]   [Full Text] [Related]  

  • 5. Lipid management with statins. The lower the better?
    Laufs U; Liao JK; Böhm M
    Z Kardiol; 2004 Jan; 93(1):4-9. PubMed ID: 14740235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.
    Stone NJ; Bilek S; Rosenbaum S
    Am J Cardiol; 2005 Aug; 96(4A):53E-59E. PubMed ID: 16098845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for aggressive lipid lowering in high-risk patients.
    Cohen JD
    J Am Osteopath Assoc; 2011 Apr; 111(4 Suppl 3):eS7-12. PubMed ID: 21593473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hyperlipidemia: decreasing lipid values and effects of statins].
    Mathes P
    Z Kardiol; 2002; 91 Suppl 2():25-9. PubMed ID: 12436762
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipid-lowering medications: what the new guidelines and data mean to women.
    Schwartz JB
    J Gend Specif Med; 2001; 4(2):9-13. PubMed ID: 11480105
    [No Abstract]   [Full Text] [Related]  

  • 11. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated guidelines support even lower cholesterol levels for at-risk patients.
    Levenson D
    Rep Med Guidel Outcomes Res; 2004 Aug; 15(15):1, 6-7. PubMed ID: 15320342
    [No Abstract]   [Full Text] [Related]  

  • 13. [LDL cholesterol--why lower and lower?].
    Müller-Wieland D; Kotzka J
    MMW Fortschr Med; 2007 May; 149(22):28-30. PubMed ID: 18069223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)].
    Klose G
    MMW Fortschr Med; 2005 Dec; 147(49-50):20. PubMed ID: 16401005
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of lipid-lowering treatment in France--the CEPHEUS study.
    Ferrières J; Gousse ET; Fabry C; Hermans MP;
    Arch Cardiovasc Dis; 2008 Sep; 101(9):557-63. PubMed ID: 19041840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein cholesterol-independent effects of statins on coronary artery disease.
    Takagi H; Umemoto T
    Am J Cardiol; 2011 Jan; 107(2):336. PubMed ID: 21211613
    [No Abstract]   [Full Text] [Related]  

  • 17. A pragmatic view of the new cholesterol treatment guidelines.
    Keaney JF; Curfman GD; Jarcho JA
    N Engl J Med; 2014 Jan; 370(3):275-8. PubMed ID: 24283199
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies.
    Kreisberg RA; Oberman A
    J Clin Endocrinol Metab; 2002 Feb; 87(2):423-37. PubMed ID: 11836262
    [No Abstract]   [Full Text] [Related]  

  • 19. Controlling lipids in a high-risk population with documented coronary artery disease for secondary prevention: are we doing enough?
    Singh M; Chin SH; Giles PD; Crothers D; Al-Allaf K; Khan JM
    Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):556-61. PubMed ID: 20305563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.